Bucladesine
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
sodium (3aR,4R,6R,6aR)-4-(6-butanamido-9H-purin-9-yl)-6-[(butanoyloxy)methyl]-2-oxo-tetrahydro-2H-1,3,5,2λ5-furo[3,4-d][1,3,2]dioxaphosphol-2-olate
|
|
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
CAS Number | 362-74-3 |
ATC code | C01CE04 (WHO) |
PubChem | CID: 28177 |
IUPHAR/BPS | 5485 |
ChemSpider | 9306 |
UNII | 63X7MBT2LQ |
ChEBI | CHEBI:50095 |
ChEMBL | CHEMBL485980 |
Synonyms | • Dibutyryl cyclic adenosine monophosphate • (N6,2'-O-dibutyryl)-adenosine-3',5'-mono-phosphate • Dibutyryl cAMP • DcAMP • DBcAMP |
Chemical data | |
Formula | C18H23N5NaO8P |
Molecular mass | 491.368 g/mol |
|
|
|
|
(verify) |
Bucladesine is a cyclic nucleotide derivative which mimics the action of endogenous cAMP and is a phosphodiesterase inhibitor.
Bucladesine is a cell permeable cAMP analog. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions. cAMP is only able to elicit minimal responses in these situations.
The neurite outgrowth instigated by bucladesine in cell cultures has been shown to be enhanced by nardosinone.
External links
- Bucladesine at the US National Library of Medicine Medical Subject Headings (MeSH)
<templatestyles src="Asbox/styles.css"></templatestyles>